Pacer Advisors
CPRX

Pacer Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Pacer Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.96M Sell
361,794
-31,939
-8% -$761K 0.03% 465
2025
Q4 		$9.19M Sell
393,733
-227,068
-37% -$5.06M 0.02% 513
2025
Q3 		$12.2M Sell
620,801
-24,331
-4% -$500K 0.03% 433
2025
Q2 		$14M Sell
645,132
-209,235
-24% -$4.94M 0.03% 400
2025
Q1 		$20.7M Sell
854,367
-2,101,141
-71% -$47.3M 0.05% 302
2024
Q4 		$61.7M Buy
2,955,508
+151,495
+5% +$3.25M 0.13% 174
2024
Q3 		$55.7M Sell
2,804,013
-163,562
-6% -$3.03M 0.12% 194
2024
Q2 		$46M Buy
2,967,575
+2,965,310
+130,919% +$46.2M 0.1% 214
2024
Q1 		$36.1K Buy
+2,265
New +$34.1K ﹤0.01% 3302
2023
Q2 		– Sell
-513,734
Closed -$8.52M – 3534
2023
Q1 		$8.52M Buy
+513,734
New +$8.48M 0.04% 451
2021
Q2 		– Sell
-10,206
Closed -$47K – 1441
2021
Q1 		$47K Buy
10,206
+1,598
+19% +$6.35K ﹤0.01% 1442
2020
Q4 		$29K Sell
8,608
-737
-8% -$2.48K ﹤0.01% 1463
2020
Q3 		$28K Buy
+9,345
New +$36.5K ﹤0.01% 1340

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Pacer Advisors's CPRX Position: Q1 2026 in Review

Pacer Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 8.1% in Q1 2026, selling an estimated $761K and leaving 361,794 shares worth $8.96M. The position accounts for 0.03% of the portfolio, ranked #465.

Pacer Advisors first reported a position in CPRX in Q3 2020 and has held it in 13 quarters since. The position peaked at $61.7M in Q4 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Pacer Advisors held 361,794 shares of Catalyst Pharmaceutical worth $8.96M as of Q1 2026.
  • Pacer Advisors sold 31,939 Catalyst Pharmaceutical shares in Q1 2026, an estimated $761K.
  • Catalyst Pharmaceutical made up 0.03% of Pacer Advisors's portfolio in Q1 2026, its #465 holding.
  • Pacer Advisors first reported a position in Catalyst Pharmaceutical in Q3 2020 and has held it in 13 quarters since.
  • Pacer Advisors's Catalyst Pharmaceutical position peaked at $61.7M in Q4 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.